Citadel Advisors’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-2,506,602
Closed -$213M 11880
2020
Q3
$213M Buy
2,506,602
+479,427
+24% +$24.2M 0.06% 185
2020
Q2
$71.8M Sell
2,027,175
-740,577
-27% -$21.7M 0.03% 575
2020
Q1
$37.3M Buy
2,767,752
+2,525,137
+1,041% +$42.5M 0.02% 791
2019
Q4
$5.13M Sell
242,615
-1,282,104
-84% -$22.6M ﹤0.01% 3048
2019
Q3
$20.2M Sell
1,524,719
-1,712,968
-53% -$25.2M 0.01% 1460
2019
Q2
$44.9M Buy
3,237,687
+3,175,235
+5,084% +$47.8M 0.02% 795
2019
Q1
$1.2M Sell
62,452
-635,297
-91% -$10.2M ﹤0.01% 5258
2018
Q4
$9.96M Sell
697,749
-501,129
-42% -$9.95M 0.01% 1896
2018
Q3
$25M Sell
1,198,878
-520,832
-30% -$12.3M 0.01% 1222
2018
Q2
$40.7M Sell
1,719,710
-101,687
-6% -$2.04M 0.02% 820
2018
Q1
$26.6M Sell
1,821,397
-2,611,787
-59% -$42.7M 0.01% 921
2017
Q4
$71.6M Buy
4,433,184
+3,270,177
+281% +$38.6M 0.04% 457
2017
Q3
$16.3M Buy
+1,163,007
New +$11.6M 0.01% 1228
2017
Q2
Sell
-301,627
Closed -$2.12M 8318
2017
Q1
$1.95M Buy
+301,627
New +$1.53M ﹤0.01% 3105
2016
Q4
Sell
-23,227
Closed -$68.7K 8104
2016
Q3
$75K Buy
+23,227
New +$65K ﹤0.01% 6749
2016
Q2
Sell
-34,000
Closed -$114K 7650
2016
Q1
$85K Sell
34,000
-13,990
-29% -$31.5K ﹤0.01% 6088
2015
Q4
$147K Buy
47,990
+19,795
+70% +$55.3K ﹤0.01% 6236
2015
Q3
$48K Buy
+28,195
New +$72K ﹤0.01% 7618
2015
Q2
Sell
-21,384
Closed -$87.4K 9251
2015
Q1
$82K Sell
21,384
-18,102
-46% -$78.7K ﹤0.01% 7008
2014
Q4
$190K Sell
39,486
-13,951
-26% -$55.1K ﹤0.01% 6032
2014
Q3
$198K Buy
53,437
+9,382
+21% +$31.7K ﹤0.01% 5738
2014
Q2
$161K Sell
44,055
-7,302
-14% -$26.8K ﹤0.01% 5807
2014
Q1
$216K Sell
51,357
-200,499
-80% -$994K ﹤0.01% 5433
2013
Q4
$1.16M Buy
251,856
+55,290
+28% +$246K ﹤0.01% 3083
2013
Q3
$1.22M Buy
196,566
+20,907
+12% +$120K ﹤0.01% 2889
2013
Q2
$956K Buy
+175,659
New +$577K ﹤0.01% 3229

Citadel Advisors's IMMU Position: Q4 2020 in Review

Citadel Advisors sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 2,506,602 shares — an estimated $213M sold.

Citadel Advisors first reported a position in IMMU in Q2 2013 and held it in 26 quarters. The position peaked at $213M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • Citadel Advisors reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • Citadel Advisors sold 2,506,602 Immunomedics Inc shares in Q4 2020, an estimated $213M.
  • Citadel Advisors first reported a position in Immunomedics Inc in Q2 2013 and held it in 26 quarters.
  • Citadel Advisors's Immunomedics Inc position peaked at $213M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.